Swiss Pharma Giant Roche to Acquire Telavant Holdings in $7.1B Deal
As a result of the $7.1 billion transaction, Roche will get the rights to develop and distribute RVT-3101 in the US and Japan. The deal is expected to be completed at the end of this year or in the first quarter of 2024. Swiss healthcare giant F. Hoffmann-La Roche AG, commonly known as
Read More